<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Animal and human data suggest a relationship between <z:chebi fb="1" ids="3098">bile acids</z:chebi>, especially secondary <z:chebi fb="1" ids="3098">bile acids</z:chebi>, and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="1" ids="9907">Ursodeoxycholic acid</z:chebi>, a synthetic <z:chebi fb="0" ids="3098">bile acid</z:chebi>, has been shown in animal and in vitro studies to reduce the risk of colonic <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development </plain></SENT>
<SENT sid="2" pm="."><plain>Human trials have focused on patients with history of <z:mpath ids='MPATH_270'>adenoma</z:mpath>, <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e>, primary sclerosing <z:mp ids='MP_0003254'>cholangitis</z:mp>, and primary <z:hpo ids='HP_0002613'>biliary cirrhosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Some studies suggest that ursodeoxycholic may reduce the <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk, but to date the studies are small, mostly retrospective, and lacking in solid evidence to support use of UDCA for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> chemoprophylaxis </plain></SENT>
</text></document>